Repligen, BMS Settle Patent Suit

Xconomy Boston — 

Repligen (NASDAQ: RGEN) of Waltham, MA, will collect $5 million from Bristol-Myers Squibb (NYSE: BMY) as part of the settlement, announced today, of a patent suit that the Massachusetts firm filed in 2006. Repligen will also collect royalties on BMS’s arthritis drug, Orencia, which Repligen and co-plaintiff the University of Michigan charged violated a patent owned by the university and the Navy and licensed exclusively to Repligen. All told, the royalties could be worth up to $117 million, according to a report in Mass High Tech.